Dexcom Inc (DXCM): Richard Doubleday , EVP, Chief Commercial Officer of Dexcom Inc sold 1,666 shares on Apr 25, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $69.15 per share for a total value of $115,205.90 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 14, 2016, John Lister (General Manager, EMEA) sold 3,704 shares at $65.78 per share price.On Apr 12, 2016, Terrance H Gregg (Executive Chairman) sold 2,169 shares at $68.00 per share price.Also, On Apr 5, 2016, Steven Robert Pacelli (EVP, Strategy & Corp. Dev.) sold 20,600 shares at $70.62 per share price.On Apr 5, 2016, Jorge A Valdes (CTO) sold 20,000 shares at $70.08 per share price.
DexCom: On Friday, Apr 22, 2016 heightened volatility was witnessed in DexCom which led to swings in the share price. The shares opened for trading at $67.5 and hit $68.87 on the upside , eventually ending the session at $68.43, with a gain of 1.11% or 0.75 points. The heightened volatility saw the trading volume jump to 4,43,708 shares. The 52-week high of the share price is $103.29 and the company has a market cap of $5,594 M . The 52-week low of the share price is at $47.92.
Company has been under the radar of several Street Analysts.DexCom is Reiterated by The Benchmark Company to Buy while Lowering the Price Target of the company shares to $ 86 from a previous price target of $105 . The Rating was issued on Feb 24, 2016.DexCom is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 74 from a previous price target of $100 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Feb 8, 2016.
Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpots data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.